M&A Deal Summary

ProBiora Health Acquires Oragenics - Consumer Probiotic Business

On June 23, 2016, ProBiora Health acquired life science company Oragenics - Consumer Probiotic Business from Oragenics for 2M USD

Acquisition Highlights
  • This is ProBiora Health’s 1st transaction in the Life Science sector.
  • This is ProBiora Health’s largest (disclosed) transaction.
  • This is ProBiora Health’s 1st transaction in the United States.
  • This is ProBiora Health’s 1st transaction in Florida.

M&A Deal Summary
Date 2016-06-23
Target Oragenics - Consumer Probiotic Business
Sector Life Science
Buyer(s) ProBiora Health
Sellers(s) Oragenics
Deal Type Divestiture
Deal Value 2M USD

Target

Oragenics - Consumer Probiotic Business

Tampa, Florida, United States
Oragenics, Inc. - Consumer Probiotic Business includes antibiotics for disease.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ProBiora Health

Dallas, Texas, United States
Category Company
Sector Life Science
DESCRIPTION

ProBiora Health LLC is a developer of antibiotics against infectious diseases.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Florida) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Oragenics

Tampa, Florida, United States
Category Company
Founded 1996
Sector Life Science
Employees5
Revenue 14M USD (2022)
DESCRIPTION

Oragenics is a developer of of novel antibiotics against infectious disease and developing effective treatments for oral mucositis. Oragenics was founded in 1996 and is based in Tampa, Florida.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Florida) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-04 Noachis Terra

United States

Noachis Terra, Inc. develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).

Buy $2M
Mergr

Product

Company

Legal